Evidence map›Paper›PMID 42128753›Full record

ArticleEuropean urology2026

IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.

Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, Nihar J Mehta, Zeynep Irem Ozay, Anika Begum, Ritika Kundra, Erin Shannon, Shayan S Nazari, Mark G Evans and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Luka CavkaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Subhiksha NandakumarMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Qingqing WuSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Nihar J MehtaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Zeynep Irem OzayHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Anika BegumMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ritika KundraMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Erin ShannonDana Farber Cancer Institute, Boston, MA, USA.
Shayan S NazariCaris Life Sciences, Phoenix, AZ, USA.
Mark G EvansCaris Life Sciences, Phoenix, AZ, USA.
Norm SmithCaris Life Sciences, Phoenix, AZ, USA.
Andrew ElliottCaris Life Sciences, Phoenix, AZ, USA.
Benzion SamueliMemorial Sloan Kettering Cancer Center, New York, NY, USA; Soroka University Medical Center, Beer Sheva, Israel.
Samson W FineMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jie-Fu ChenMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Philip W KantoffConvergent Therapeutics, Inc, Cambridge, MA, USA.
Pedro Isaacsson VelhoSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Hao WangSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
David E SaninSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Eliezer M Van AllenDana Farber Cancer Institute, Boston, MA, USA.
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Wassim AbidaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Tamara L LotanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Nikolaus SchultzMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Emmanuel S AntonarakisMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Laura A SenaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Electronic address: laura.sena@jhmi.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
A study of IDH1-mutant prostate cancer to identify novel therapeutic targetsR21CA292179 · NCI · JOHNS HOPKINS UNIVERSITY · PI SENA, LAURA A. · 2024 to 2024
$421k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA292179
6 · The paper itself

Abstract

Prostate cancer with isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutation appears to be a unique molecular subclass, but its associated clinical features have not been previously described. Here, we performed a retrospective analysis of clinical and molecular features of prostate cancer with IDH1 p.R132 or IDH2 p.R172 mutations. A series of 99 IDH1-mutated and 12 IDH2-mutated cases was identified using genomics databases at multiple institutions. An IDH1/2 wild-type control cohort was generated with matched clinical features at diagnosis. IDH-mutated cases frequently presented with localized disease (91%), but exhibited high tumor stage (42% T3) and grade (54% grade group 5). Compared with matched controls, patients with IDH1 mutations exhibited longer overall survival (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.04-0.68; p = 0.01), metastasis-free survival (HR, 0.22; 95% CI, 0.09-0.58; p = 0.002), and progression-free survival on hormonal therapy (HR, 0.35; 95% CI, 0.16-0.76; p = 0.036). IDH1-mutant cases were enriched for concurrent activating mutations of FOXA1 and CTNNB1 and tended to lack TMPRSS2-ERG fusions, SPOP mutations, and RB1 alterations. IDH1 mutations were associated with global transcriptional repression and evidence of metabolic and epigenetic reprogramming. These results depict IDH-mutant prostate cancer as a subtype that can present with high tumor stage and grade, but is associated with favorable outcomes.

Indexed as

Cancer genomicsIDH mutationsProstate cancer

Identifiers

PMID42128753
PMCPMC13178107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.